Rituximab biosimilar - Dr Reddy's Laboratories

Drug Profile

Rituximab biosimilar - Dr Reddy's Laboratories

Alternative Names: DRL-rituximab; DRL_RI; Reditux; Tidecron

Latest Information Update: 13 Feb 2017

Price : $50

At a glance

  • Originator Dr Reddys Laboratories
  • Developer CinnaGen; Dr Reddys Laboratories
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Non-Hodgkin's lymphoma; Rheumatoid arthritis
  • Phase II Diffuse large B cell lymphoma

Most Recent Events

  • 03 Dec 2016 Adverse events, pharmacokinetics and pharmacodynamics data from a clinical trial in Diffuse large B-cell lymphoma presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
  • 15 Jul 2013 Biomarkers information updated
  • 30 Apr 2007 Launched for Non-Hodgkin's lymphoma in India (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top